SCHEMBL3675196

SCHEMBL3675196

Cc1ccc2cc(-c3cncc(Nc4cc(-c5cc6ccc(C)cc6n5C)cnc4C(N)=O)c3)n(C)c2c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.40
XDH P47989 2/20 0.37
SLC22A12 Q96S37 2/20 0.37
SYK P43405 4/20 0.35
KCNH2 Q12809 2/20 0.35
SIRT2 Q8IXJ6 2/20 0.34
SIRT1 Q96EB6 2/20 0.34
SIRT3 Q9NTG7 2/20 0.34
DHODH Q02127 2/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
PFKFB3 Q16875 1/20 0.34
PIK3CB P42338 1/20 0.33
KDR P35968 3/20 0.33
PDGFRB P09619 2/20 0.33
CDK4 P11802 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CCND3 P30281 1/20 0.32
CDK6 Q00534 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3684933 0.88 CYP11B2 (0.44) CYP11B2XDHSLC22A12
SCHEMBL1606613 0.72 IRAK4 (0.44) CYP11B2IRAK4
SCHEMBL3678379 0.72 CYP11B2 (0.35) CYP11B2KDRPDGFRB
SCHEMBL1606931 0.72 CYP11B2 (0.49) CYP11B2PIK3CB
SCHEMBL3682202 0.70 CYP11B2 (0.38) CYP11B2CDK2
SCHEMBL3683054 0.67 MAP4K4 (0.46) CYP11B2SIRT2SIRT1SIRT3
SCHEMBL1606155 0.65 CYP11B2 (0.54) CYP11B2SIRT2SIRT1SIRT3
SCHEMBL1606088 0.65 HTT (0.40) CYP11B2
SCHEMBL27957080 0.64 KMT2A (0.36)
SCHEMBL16480591 0.64 PLA2G10 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307371-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2017-10-04 EP disclosed
US-9242963-B2 Organic compounds NOVARTIS AG (CH) 2016-01-26 US disclosed
US-20150210672-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-07-30 US disclosed
US-20140288126-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-25 US disclosed
US-8791141-B2 Organic compounds NOVARTIS AG (CH) 2014-07-29 US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 US disclosed
WO-2009156462-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261698-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 13/4885XDH 227/4885SLC22A12 343/4885
US-20150210672-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 12/4885XDH 217/4885SLC22A12 354/4885
US-20140288126-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 12/4885XDH 217/4885SLC22A12 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.